Physician profile
Bruce S Bashline
NPI 1912015132
$5,487.32
in general payments reported to CMS, 2019-2025
34 companies · $791 in 2025
The $791 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $962 · 2020: $682 · 2021: $1,086 · 2022: $569 · 2023: $682 · 2024: $716 · 2025: $791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,188.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,320.36 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $803.90 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $721.99 | 2019-2024 | Xifaxan |
| Novo Nordisk INC | $495.27 | 2019-2024 | Wegovy |
| Glaxosmithkline, LLC. | $329.84 | 2019-2023 | Trelegy Ellipta |
| Pfizer INC. | $220.17 | 2019-2025 | |
| Amgen INC. | $174.40 | 2019-2023 | Repatha, Otezla |
| Aimmune Therapeutics, INC. | $162.35 | 2024-2025 | Zenpep |
| E.R. Squibb & Sons, L.L.C. | $147.06 | 2024-2025 | Eliquis, Camzyos |
| Teva Pharmaceuticals USA, INC. | $140.19 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $93.68 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.86 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $78.73 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $75.95 | 2020-2025 | Rexulti |
| Bausch Health US, LLC | $68.13 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $66.19 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Allergan, INC. | $60.18 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.21 | 2019-2021 | |
| Exact Sciences Corporation | $52.72 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $50.83 | 2022 | |
| Astellas Pharma US INC | $47.09 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $37.00 | 2024 | |
| Lundbeck LLC | $22.46 | 2023 | Vyepti |
| Dexcom, INC. | $21.26 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.14 | 2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $19.30 | 2025 | Fanapt |
| Radius Health, INC. | $18.31 | 2025 | |
| Inspire Medical Systems, INC. | $17.76 | 2023 | Inspire |
| Phathom Pharmaceuticals, INC. | $16.88 | 2025 | Voquezna |
| Amarin Pharma, INC. | $16.11 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.27 | 2021 | |
| Ironshore Pharmaceuticals INC. | $13.58 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.35 | 2019 | |
| Concordia Pharmaceuticals INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Bashline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.